Imagine trying to identify every type of person in a crowded stadium — not by asking them, but by the badges they are wearing. That is essentially what flow cytometry does for blood cells. Every cell in your body carries a distinctive set of protein markers on its surface, and these markers betray what type of cell it is, what stage of maturity it has reached, and whether something has gone wrong. Flow cytometry is the tool that reads those markers, one cell at a time, thousands of cells per second.
In modern hematology, flow cytometry has become indispensable. No leukemia or lymphoma diagnosis is complete without it. It is used not only to identify the type of blood cancer, but also to monitor treatment response, detect minimal residual disease, and distinguish between reactive and malignant conditions. Understanding how it works helps patients and families make sense of the reports that come back from the lab.
The Basic Principle
Flow cytometry measures cells as they pass, one by one, through a narrow stream in front of laser beams. Before they enter the machine, the cells are stained with antibodies that bind to specific surface markers. Each antibody is attached to a fluorescent dye, and each dye glows at a different colour when illuminated by the laser. By measuring which colours light up on each cell, the machine can determine which markers that cell carries — and therefore what type of cell it is.
The markers are called CD antigens (short for 'cluster of differentiation'). There are hundreds of them, numbered sequentially — CD3, CD4, CD8, CD19, CD20, CD34, CD45, and so on. Each type of blood cell has a characteristic combination of CD markers, known as its immunophenotype. For example, mature T-cells express CD3, B-cells express CD19 and CD20, and hematopoietic stem cells express CD34. By looking for combinations of markers, the laboratory can identify cells with remarkable precision.
Gating and Interpretation
When a flow cytometry sample is analyzed, the data is displayed as scatter plots — two-dimensional graphs where each dot is a single cell. A typical plot might show CD45 (a marker on all white blood cells) on one axis and side scatter (a measure of cellular complexity) on the other. Different cell populations appear in different regions of the plot: lymphocytes are bright for CD45 and have low side scatter; granulocytes have intermediate CD45 and high side scatter; and blast cells — immature precursors that are rarely seen in healthy blood — appear in a characteristic dim CD45 region with low side scatter.
The analyst draws 'gates' around each population and then looks at the marker profile of the cells within each gate. By working through a panel of antibodies, they can identify each population, count its abnormal features, and determine whether something does not fit normal patterns.
Diagnosing Leukemia with Flow Cytometry
When a patient presents with possible leukemia, flow cytometry is one of the first tests ordered after a bone marrow aspirate. The question the flow cytometrist is trying to answer is: are there abnormal cells, and if so, what lineage and maturation stage do they belong to?
In acute leukemia, the first question is whether the blast cells are of myeloid or lymphoid origin. Myeloid blasts typically express CD13, CD33, CD117, and myeloperoxidase (MPO). Lymphoid blasts express markers specific to their lineage — B-cell lymphoblasts express CD19 and CD10, while T-cell lymphoblasts express CD7 and cytoplasmic CD3. This distinction is critical because AML and ALL are treated very differently. In some cases, blasts express markers of multiple lineages — a condition called mixed phenotype acute leukemia — which has its own treatment considerations.
In chronic leukemias, flow cytometry helps confirm the diagnosis and distinguish subtypes. CLL has a very characteristic immunophenotype: CD5+, CD23+, CD19+, CD20 (dim), with monoclonal light chain expression. The Matutes score uses these markers to distinguish CLL from other B-cell lymphoproliferative disorders. For mantle cell lymphoma, the typical pattern is CD5+, CD23−, with high CD20 and often cyclin D1 expression.
Flow Cytometry in Lymphoma
Flow cytometry is also essential in evaluating lymphoid tissues, whether from lymph node biopsies or body fluids. B-cell lymphomas are identified by detecting a monoclonal population — all of the abnormal B-cells express either kappa or lambda light chains (not both, as a healthy polyclonal B-cell population would). This demonstration of light chain restriction is one of the simplest and most reliable ways to confirm that a lymphoid infiltrate is neoplastic rather than reactive.
Different lymphoma subtypes have different characteristic marker profiles, and flow cytometry contributes to classification along with morphology, immunohistochemistry, and molecular testing. For indolent lymphomas like follicular lymphoma, flow can help distinguish from benign follicular hyperplasia. For aggressive lymphomas like diffuse large B-cell lymphoma, additional tests are often needed, but flow provides rapid initial characterization.
Minimal Residual Disease: Watching Treatment Work
One of the most important modern applications of flow cytometry is detecting minimal residual disease (MRD) — the very small number of cancer cells that may remain after treatment, below the threshold of detection by microscopy. MRD monitoring is particularly important in ALL, AML, and CLL, where the depth of response predicts long-term outcome.
Modern flow cytometry panels can detect as few as 1 leukemic cell in 10,000 to 100,000 normal cells. Patients who achieve MRD negativity after treatment generally have much better outcomes than those who remain MRD positive. This information is now routinely used to adjust treatment intensity — for example, intensifying therapy or pursuing transplant for MRD-positive patients, or reducing therapy for those who achieve deep remissions.
Reactive vs Malignant: An Important Distinction
Not every abnormal blood count or enlarged lymph node reflects cancer. Many conditions cause reactive changes — benign increases in certain cell populations in response to infection, inflammation, or other stimuli. Flow cytometry is often the fastest way to distinguish a reactive process from a malignant one. A reactive B-cell population will be polyclonal (both kappa and lambda light chains present in a balanced ratio), whereas a neoplastic B-cell population will be monoclonal (essentially all one light chain type).
This distinction matters enormously for patients. A reactive lymphocytosis caused by a viral infection requires no treatment beyond watchful waiting, while a new leukemia or lymphoma requires urgent hematologic care. Flow cytometry often provides the answer quickly.
Limitations and Complementary Tests
Flow cytometry is powerful, but it is not a complete diagnostic test on its own. It relies on surface markers, which can sometimes be ambiguous. It does not reveal morphology or tissue architecture. It cannot detect most genetic mutations or chromosomal abnormalities. For these reasons, flow cytometry is always interpreted in conjunction with morphology (peripheral blood smear and bone marrow review), cytogenetics, and molecular testing.
A hematologist integrates all of these data streams to reach a final diagnosis. It is rarely any single test that provides the answer — it is the pattern across multiple tests, interpreted by an experienced specialist, that leads to the correct diagnosis and treatment plan.
What Patients Should Know
When you or a loved one has flow cytometry performed, the report may look intimidating — long lists of CD markers with percentages and intensity descriptors. You do not need to memorize them. What matters is the conclusion: what population was identified, what diagnosis it supports, and what treatment implications it has. Your hematologist can walk you through the report and explain how it fits into the overall picture of your diagnosis.
Flow cytometry is quiet, precise, and remarkably powerful. Each second, it reads the molecular labels on thousands of cells, building a detailed portrait of what is happening in the blood or marrow. For patients with blood disorders, that portrait is often the key to understanding what is wrong — and what to do about it.